Lipid nanocarrier covered with polymer applied to the diagnosis and treatment of pathologies from central nervous system by intranasal delivery of therapeutic agents

• Grant number: 18/17911-0
• Support type: Scholarships in Brazil - Post-Doctorate
• Effective date (Start): February 01, 2020
• Effective date (End): January 31, 2022
• Field of knowledge: Health Sciences - Pharmacy - Pharmaceutical Technology
• Principal Investigator: Antonio Claudio Tedesco
• Grantee: Hellen Franciane Gonçalves Barbosa
• Home Institution: Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto (FFCLRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil

Abstract

This study aims the treatment of diseases from Central nervous system (CNS), as Schizophrenia, Parkinson's and Alzheimer's and one high aggressive kind the neoplastic diseases the head cancer Glioblastoma Multiforme (GBM) Grade IV, these pathologies require systemic delivery of therapeutics for the brain to enable treatment. Reach this region is still a challenge, due the impervious nature of the endothelial membrane separating the systemic circulation and central interstitial fluid, the blood-brain barrier. A recent approach proposes the nose-to-brain transport as an alternative. The intranasal drug delivery is attractive strategy, since it is not invasive and is able to allows the efficiently compounds delivery when encapsulated in lipid nanocarriers, especially which have on their surface cationic species, such as the chitosan biopolymer. This project aims the preparation of solid lipid nanoparticles (NLS) and nanostructured lipid carriers (CLN) modified with cationic polymers for therapeutic agents delivery, photosensitizing drugs such as aluminum chlorthal phthalocyanine (ClALPc) as well the siRNAs. In such way, the objective is study the encapsulation and delivery efficiency by intranasal administration of photosensitizing drugs active in the photochemical-therapeutic treatment of tumor tissues also siRNA, able to silence a specific gene expression by the cleavage of specific mRNA. Thus, the approach of the project is in the association of the type of active to be investigated (photosensitive drugs and the siRNA) and the efficiency of covered lipid nanocarriers. Therefore, it aims to diagnose and modulate therapeutic agents delivery for GBM grade IV and thus propose a promising approach for treatment of neurodegenerative pathologies of CNS. (AU)